Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/45832
Title: | Hyperadrenocorticism in Dogs | Authors: | Behrend, Ellen N. Melián Limiñana, Carlos |
UNESCO Clasification: | 310907 Patología | Keywords: | Trilostane Treatment Cushings-Disease |
Issue Date: | 2013 | Journal: | Clinical Endocrinology of Companion Animals | Abstract: | This chapter discusses the pathogenesis, classical signs, diagnosis, and treatment for hyperadrenocorticism (HAC) in dogs. The clinical signs of HAC result from chronically elevated serum cortisol concentrations. More than 80% of dogs with HAC have pituitary-dependent disease due to an adrenocorticotropic hormone (ACTH)-secreting adenoma; approximately 80% originate in the adenohypophysis and 20% in the intermediate lobe. Older, small breed dogs are predisposed to spontaneous HAC. Tests for spontaneous HAC are divided into screening tests, meant to determine if HAC is present, and differentiating tests, designed to ascertain whether the disease is pituitary-or adrenal-based. Selegiline inhibits the enzyme monoamine oxidase B and, as a result, increases hypothalamic dopamine concentrations, which, in turn, inhibit ACTH secretion from the intermediate lobe of the pituitary. Selegiline is effective in at most 20% of cases of pituitary-dependent HAC. | URI: | http://hdl.handle.net/10553/45832 | ISBN: | 9781118997093 | DOI: | 10.1002/9781118997093.ch5 | Source: | Clinical Endocrinology Of Companion Animals, p. 43-64, (2013) |
Appears in Collections: | Capítulo de libro |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.